España
Vacuna Covid-19: la OMS considerará la lista de uso de emergencia de Covovax la próxima semana.
Nevertheless, within the limitations of comparing between non-randomised cohorts, SARS-CoV-2 anti-spike IgG titres induced by BNT/NVX were still above that of homologous ChAd, a schedule with demonstrated effectiveness of 65–70% against symptomatic SARS-CoV-2 infection and over 90% against hospitalisation and death.
39. Additionally, the T-cell response across all groups was greatest with ChAd/NVX, which might prove important in terms of durability of protection and protection against new SARS-CoV-2 variants.40. These data align with real-world evidence of robust effectiveness of mixed schedules against disease.24
ChAd/NVX showed the highest cellular response as measured by IFN-γ ELISPOT, and is similar to that seen with ChAd/BNT at a 28 day boost interval.
8
Of the mixed schedules studied, perhaps the most relevant to these countries is the ChAd/NVX, given that neither of these vaccines require ultra-low temperature storage and the low cost of ChAd. NVX has recently been the subject of a WHO Emergency Use Licence and should become available under the COVAX scheme.
42
This study has a number of limitations. The age range (50–78 years) and ethnicity (90·7% of participants primed with ChAd and 94·7% of those primed with BNT self-identified as White) of the study cohort limit generalisability of the reactogenicity and immunology results to younger populations and people who are not of White ethnicity.
It is interesting to note that in the groups receiving an NVX boost, there is a modest increase in antibody titres after day 7; although the samples' size are small, this finding warrants further investigation.
Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....
